Generic Name
Ribociclib SuccinatePacks Price
- Tab 200 mg: 21: 166130.66: 195447.84
- Tab 200 mg: 42: 269167.00: 316667.00
- Tab 200 mg: 63: 403750.00: 475000.00
Kisqali
Therapeutic Group
Endocrine Hormone TherapyIndication Dosage
Ribociclib Succinate, marketed under the brand name Kisqali, is a medication primarily prescribed for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. It is used in combination with other hormonal therapies to inhibit the progression of the disease in postmenopausal women, offering hope and improved outcomes in the fight against this form of breast cancer.
Aromatase Inhibitor For The Treatment Of Pre/perimenopausal Or Postmenopausal Women With Hormone Receptor (hr)-positive, Human Epidermal Growth Factor Receptor 2 (her2)-negative Advanced Or Metastatic Breast Cancer, As Initial Endocrine-based Therapy Or Following Disease Progression On Endocrine Therapy:
- Adult: 600 Mg (three 200 Mg Tablets) Taken Orally, Once Daily With Or Without Food, For 21 Consecutive Days Followed By 7 Days Off Treatment Resulting In A Complete Cycle Of 28 Days.
- Children: Not Recommended.
Content
- Tab 200mg: Ribociclib Succinate 200mg
Pregnancy
Contraindicated In Pregnancy.
Stability
- Aromatase Inhibitor
Contra Indications
- None Known
Precautions
- None Known
Lactation
- Contraindicated. Discontinue Breast-feeding
Side Effects
- Headache
- Abdominal Pain
- Anemia
- Alopecia
- Insomnia
- Dyspnea
- Back Pain
- Nausea
- Diarrhea
- Qt Interval Prolongation
- Vomiting
- Constipation
- Stomatitis
- Decreased Appetite
- Rash
- Pruritus
- Fatigue
- Pyrexia
- Abnormal Liver Function Tests
- Urinary Tract Infection.
- Rare: Neutropenia
- Leukopenia
- Lymphopenia
- Edema Peripheral
- Interstitial Lung Disease (ild)
- Pneumonitis
- Hepatobiliary Toxicity
Author
Shahid Arif